內克塔治療 NKTR 深 滬
已收盤 01-09 16:00:00 美东时间
39.71
-1.730
-4.17%
華盛通- 最 高41.89
- 今 開41.20
- 成交量 73.44万股
- 最 低 39.61
- 昨 收 41.44
- 總市值 8.08亿
- 52周最高 66.92
- 市盈率 靜 --
- 換手率 3.61%
- 52周最低 6.48
- 委 比 -68.62%
- 總股本 2034.16万
- 歷史最高 1670.40
- 量 比 1.32
- 振 幅 5.50%
- 歷史最低 6.189
- 每 手 1
- 風險率 19.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
Septerna, Inc. announced the appointment of Mark A. Wilson as Chief Legal Officer. With over 25 years of experience in intellectual property, corporate law, and strategic collaborations, Wilson joins from Nektar Therapeutics, where he served as Senior Vice President and Chief Legal Officer. His expertise is expected to strengthen Septerna’s governance and maximize the value of its Native Complex Platform™, which advances GPCR drug discovery. Wils...
01-08 21:05
FlexShares International Quality Dividend Index Fund declares quarterly distribution of $0.4694
FlexShares International Quality Dividend Index Fund (IQDF) - $0.4694. Payable Dec 26; for shareholders of record Dec 19; ex-div Dec 19. More on Oracle Q2 Earnings: Don't Catch The Falling Knife Itali...
2025-12-19 23:53
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.
2025-12-17 00:30
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Shares of B Riley Financial Inc (NASDAQ:RILY) rose sharply in pre-market tradin...
2025-12-16 18:53
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
<p>Abeona Therapeutics Inc. announced the appointment of Mohamad Tabrizi as Senior Vice President and Chief Business Officer. Tabrizi will lead corporate strategy, business development, and operational efficiency. He brings extensive experience in strategic planning, venture capital, and corporate development, including successful transactions with major pharmaceutical companies. Previously, he held roles as a General Partner at Pandect Bioventur...
2025-12-15 12:30
AI adopters trade gaining steam; top stocks in AI adoption sectors
Wall Street research looks to be shifting from endorsing the classic AI trade to AI adopters. Instead of the chipmakers and hyperscalers in the megacap sectors (XLK) (XLC) (XLY) that are making AI pos...
2025-12-09 17:28
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Dec. 5, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that the Organization and Compensation Committee of Nektar's Board of Directors granted non-qua...
2025-12-06 07:00
Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders
Submits Recalculated Initial Offer of $4.75 Based on Board's Value Destructive Actions Nominated Two Independent Candidates to Restore Oversight and Protect Shareholders Urges Shareholders t...
2025-12-03 07:48
Citigroup Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $102
Citigroup analyst Samantha Semenkow initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Buy rating and announces Price Target of $102.
2025-11-27 03:17
